Ligand Pharmaceuticals | LGND - Sales Revenues


Ligand Pharmaceuticals reported $59.66M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Agenus USD 34.2M 3.97M Dec/2025
Amgen USD 9.9B 340M Dec/2025
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Baxter International USD 2.97B 130M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Enviri Corporation USD 555M 19.81M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Intrexon USD 717K 511K Jun/2024
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
MacroGenics USD 41.23M 31.61M Dec/2025
Merck USD 16.4B 880M Dec/2025
Pacira USD 196.87M 17.35M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Veracyte USD 140.6M 8.7M Dec/2025